Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  November 16, 2022 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) ___________________   Delaware       1-07151       31-0595760 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)   1221 Broadway , Oakland , California    94612-1888 (Address of principal executive offices) (Zip code)   ( 510 ) 271-7000 (Registrant's telephone number, including area code)   Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)   [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered Symbol(s) Common Stock - $1.00 par value CLX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company            ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.            ☐ Item 5.07 Submission of Matters to a Vote of Security Holders. On November 16, 2022, The Clorox Company (the “Company”) held its virtual annual meeting of shareholders. The matters voted on and the results of the vote were as follows: 1. The Company’s shareholders elected the following directors to each serve until the next Annual Meeting of Shareholders or until a successor is duly elected and qualified.         Number of Votes         For       Against       Abstain       Broker Non-Votes Amy L. Banse    85,257,601       1,090,707       260,962       18,222,827    Julia Denman 85,663,547 679,455 266,267 18,222,827 Spencer C. Fleischer 84,833,382 1,491,959 283,930 18,222,827 Esther Lee 85,460,628 888,455 260,187 18,222,827 A.D. David Mackay 85,544,613 790,520 274,137 18,222,827 Paul Parker 85,692,013 641,810 275,448 18,222,827 Stephanie Plaines 85,600,327 743,060 265,883 18,222,827 Linda Rendle 85,542,167 802,236 264,867 18,222,827 Matthew J. Shattock 84,014,161 2,326,236 268,874 18,222,827 Kathryn Tesija 85,386,553 959,875 262,842 18,222,827 Russell J. Weiner 85,520,082 803,127 286,061 18,222,827 Christopher J. Williams 85,277,028 1,054,292 277,951 18,222,827   2. The Company’s shareholders voted for (on an advisory basis) the approval of the compensation of the Company’s named executive officers.   Number of Votes For       Against       Abstain       Broker Non-Votes 80,870,158 5,199,569 539,543 18,222,827   3. The Company’s shareholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023.   Number of Votes For       Against       Abstain       Broker Non-Votes 102,642,634 1,870,724 318,740 0 Item 9.01 Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below. EXHIBIT INDEX Exhibit Description   104       Cover Page Interactive Data File (embedded within the Inline XBRL document)   SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CLOROX COMPANY   Date: November 17, 2022 By:          /s/ Angela Hilt Angela Hilt Executive Vice President – Chief Legal Officer